Special Situation Report:

Date: November 08, 2004

Our Feature Profile:

Swiss Medica Inc.

(OTC BB: SWME)

Company Profile

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. The company increases its market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission may soon be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com, and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMSEscape which holds US Patent #'s 5760014 and 5612320. PMSEscape is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit www.pmsescape.com for additional information and ordering details.

About The Company:

In addition to information in the company profile, Swiss Medica has built an experienced management team with over 100 years of blue chip experience in operational management, sales, marketing, e-commerce, corporate finance, mergers and acquisitions and business development. Their team has relationships with the senior management teams of leading health product sales organizations, including leading North American retailers. Swiss Medica’s first all-stock acquisition is a patented (US 6,444,238 B1), non-doping essential oil product line (called ”024™”) that relieves pain and reduces swelling. Topically applied pain relief is a worldwide multi-billion dollar market. In addition, this essential oil product line includes formulations for menstrual cramps, cold sores, hemorrhoids and nasal congestion.

024’s founders spent 10 years and $10 million building a loyal following for 024™ in the European sports and medical communities, and have secured extremely exciting product testimonials and endorsements from the sports, hospital and medical communities in Europe. (e.g. A major German hospital and several German medical clinics, Norwegian/Swiss Olympic Ski Teams, German Olympic Track & Field Team and other leading sports teams and hospitals).

Swiss Medica’s experienced management team is confident that it can leverage 024’s strong product attributes, patent protection and blue chip endorsements to generate significant revenues.

Swiss Medica’s future acquisition plans are focused on securing chronic aliment bioscience products in high potential areas such as diabetes and cholesterol.

Products:

Products

• 024™ Pain Neutralizer -- 024™ Pain Neutralizer is created from the earth's most potent healing botanicals. All the ingredients are derived from the best-sourced botanicals on earth: camphor oil (white) (Japan), eucalyptus oil (Australia), aloe vera oil (Mexico), peppermint oil (India), rosemary oil (Spain), lemon oil (USA) and orange oil (USA).
• PMS Escape (NEW) -- PMS Escape is a dietary supplement developed for women with normal PMS-related disturbances in mood and appetite. PMS Escape is a patented, clinically proven combination of specially formulated simple and complex carbohydrates plus vitamins and minerals, prepared specifically to manage some of the normal mood and appetite-related disturbances women experience during the premenstrual period.

Key Management:

• Raghu Kilambi is the CEO and co-founder Swiss Medica and led the launch of Swiss Medica, including building its management team and securing financing.
• Grant Johnson is the President & COO of Swiss Medica and is responsible for leading the company's sales team, and ensuring the market success of Swiss Medica's product line.
• Bruce Fairbairn is the CFO of Swiss Medica and he brings nearly 30 years of proven experience as a financial analyst, internal auditor and Chief Financial Officer.
• Tom Quinn is the Executive Vice President, and began his career with Procter and Gamble, where he progressed through a range of sales and marketing positions in the U.S. and the UK.
• Anne Dundon is the VP, Canadian Sales, and began her career with Procter and Gamble as a sales representative.
• Robert Esson is the VP, Logistics and Supply Chain Management, and spent the first 15 years of his career with The Quaker Oats Co., and progressed through several operations and logistics positions in the U.S. and overseas.
• Robert Klein is the VP, Strategic Planning and Budgeting, and successfully ran his own consulting firm for 7+ years where he provided clients with strategic planning, financing and research services.
• Wendy Kramer is the Vice President, and she is responsible for generating over $25 million in new business for a number of startup and corporate operations over the past decade.

SEC Filings:

SEC filings for Swiss Medica, Inc., can be reviewed at: http://finance.yahoo.com/q/sec?s=SWME.OB

Share Structure:

Latest Press Releases:

	08/12/04		SWISS MEDICA INC Files SEC form 10QSB, Quarterly Report
	05/17/04		SWISS MEDICA INC Files SEC form 10QSB, Quarterly Report

Contact Information:

Technical Analysis

Conclusion

Chart analysis and company fundamentals present a stock that is worthy of higher prices! The commericialization of its proprietary bioscience products show a great deal of promise and excellent growth potential for the company. We believe the stock is destined for appreciation!

Disclaimer and Disclosure

© 2004 StockChartist.com, LLC. All rights reserved. StockChartist.com, LLC is not a Registered Investment Advisor or a Broker / Dealer.

All materials presented on our web site and individual reports released to the public are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with trading any stock, there is always a high degree of investment risk and volatility. All investors are cautioned that you may lose all or a portion of your investment if you decide to make a purchase in any profiled company. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

This stock profile/advertisement alert contains or incorporates by reference "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements" within the meaning of the Safe Harbor Clause of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements invoke risk and uncertainties that may cause the Company's actual results to differ materially from such forward-looking statements. Forward looking statements in this action may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or that by statements indicating certain actions “may”, “could”, or “might occur”, and similar expressions which are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, demand for the Company's product both domestically and abroad, the Company's ability to continue to develop its market, the Company's ability to obtain necessary financing, general economic conditions, and other factors that may be more fully described in the company's literature and any periodic filings with the Securities and Exchange Commission.

It should be understood that there is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information on our web site or within our report is only as reliable as the sources they were obtained from. Stockchartist.com, LLC does not hold positions in securities mentioned herein, since that may be regarded as a conflict in interest. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Stockchartist.com, LLC did not receive any form of compensation from any source for its efforts in presenting and disseminating this information to our subscriber database, and posting this report on the Stockchartist.com, LLC web site. Stockchartist.com, LLC will not trade the subject stock at any time.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

Back to our Home Page